Correct, they will have data to assess HOMA-IR ratio/index over time as a proxy of insulin resistance. Recall that in post hoc analysis of SUSTAIN and ASSURE trials, glucose was significantly lowered in the diabetic patients treated with apabetalone for 6 months. It will be interesting to see if that holds up in the longer and larger BETonMACE trial. 

As for BETonMACE ages, the original protocol is aiming for 1440 patients under 65 and 960 patients over 65. So hopefully that will allow insight into the potential of apabetalone to delay the onset or improve dementia/Alzheimers disease.